CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

Get full, unrestricted access to all of ch-aviation's news and data for 14 days.

DISCLAIMER: This site and the products offered are for entertainment purposes only, and there is no gambling offered on this site. This service is intended for adult audiences. No guarantees are made ...

Automate Google account creation using Puppeteer with this script, which auto-fills the registration form and handles verification steps.